This trial is evaluating whether Urotronic Drug Coated Balloon (DCB) will improve 1 primary outcome and 1 secondary outcome in patients with Stricture Urethra. Measurement will happen over the course of 90 days post-procedure.
This trial requires 50 total participants across 1 different treatment group
This trial involves a single treatment. Urotronic Drug Coated Balloon (DCB) is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
"The pathology of constrictive periurethral fibrosis, which is typically seen in the postpartum uterine period and may coincide with the onset of menopausal symptoms, will lead to constrictive changes in the uterine vasculature. The pathogenesis of uterine vessel constriction is not well understood." - Anonymous Online Contributor
"There are many techniques that can be applied for constriction, including surgical, nonsurgical, and nonsurgical and conservative approaches. Minimally invasive surgical procedures are an intriguing potential future alternative to conventional surgical approaches." - Anonymous Online Contributor
"(1) All constrictive lesions have unpredictable healing, even in cases with no residual symptoms; (2) constrictive lesions are not always asymptomatic, and symptoms may vary from patient to patient; (3) most cases of symptomatic constrictive lesions will resolve spontaneously or spontaneously in a short time; and (4) most cases of asymptomatic constrictive lesions may regress spontaneously. Therefore, cure cannot be accomplished by constrictive procedures, because the unpredictable, unpredictable, and unpredictable healing have to be accounted for." - Anonymous Online Contributor
"The definition of constriction, pathologic, is important for the diagnosis and treatment of constriction of the esophagus due to chronic diseases, especially diabetes, in the general population, and especially in children, because it determines patient presentation and treatments. As a result, it is a simple and easy-to-detect finding." - Anonymous Online Contributor
"Signs of constriction were often nonspecific, including lethargy, anhedonia (loss of interest in activities for which the patient is highly motivated), dysphoria, and apathy (loss of the capacity to feel pleasure and pleasure). The hallmark of constriction, ileus and ileoscopy, are indications of the chronicity of the disorder, and are usually not present." - Anonymous Online Contributor
"The disease of constriction, pathologic will have a nearly 10-fold increase in diagnosis over the next three decades in the United States. It is estimated that 15 people per year will be diagnosed with constriction, pathologic over the same period." - Anonymous Online Contributor
"There is no evidence suggesting that any treatments can improve the quality of life of patients with constriction, pathologic. More than half of the patients would like to receive such treatment to relieve their distress, with the exception of stoma closure. Patients with constriction, pathologic are able to live at many levels of their quality of life. There is a need to develop a holistic approach of treatments for patients presenting constriction, pathologic." - Anonymous Online Contributor
"Data from a recent study has shown that when combined with PTA, the DCB with anti-platelet coated surface has significantly fewer and less severe adverse events than with unfurter PTA and is more effective in reducing pain without causing complications. Use of DCB in combination with PTA could be a better alternative in the treatment of the arteries of patients with carotid stenosis. Additional studies may be necessary to further examine this use." - Anonymous Online Contributor
"It is not uncommon for urotronic coating agents to be associated with the side effect of burning pain on the urethra, lower urinary tract, or renal artery. While burn pain has been reported to be transient, it may be severe in some patients. Patients at risk of serious burns during ureteral deployment of ureteral stent are at an increased risk for this common complication. Patients undergoing this procedure before renal artery involvement has an increased risk of renal arterial thrombosis as well." - Anonymous Online Contributor
"[Previous dcb studies have led to new research in the use of Dcb for the treatment of achalasia] (https://www.clinicaltrials.gov/ct2/show/NCT01645487?). [The studies have shown that use of urotronic Dcb is an effective new drug for treating achalasia, with improvement in symptoms seen after treatment." - Anonymous Online Contributor
"The most common cause of constriction, pathologic is fibrosis and scarring due to vascular damage and chronic inflammatory reaction. These vascular scars are more frequently observed in the context of pathologies associated with a low BMI since the vessels are at a higher risk of intimal hyperplasia due to a lack of proper stimulation of vascular endothelial growth factor (VEGF)." - Anonymous Online Contributor
"The newest development of DCB is with novel DCB coated with sertoli cell protein and spermine. These compounds act as 'coadjuvers' that help improve balloon's retention leading to sustained durations of thermal balloon application that may afford longer periods of vessel cooling leading to better clinical outcomes." - Anonymous Online Contributor